ERBB2 and breast carcinoma: Cuzick et al. and Sheri et al. described the use of IHC4 (values by immunohistochemistry of ER, PR, Her2/neu, and Ki67) with similar predictive intention in early breast cancer and neoadjuvant concepts [21, 22].